Daily Cosmetic Research Analysis
Today's top cosmetic-related studies span safety, mechanistic cosmeceuticals, and complication surveillance. A 90-day rat study delineates dose-dependent neurotoxicity of silver nanoparticles used in cosmetics, while hydroxyproline-containing cyclic dipeptides from collagen suppress UVB-induced inflammatory pathways and penetrate human skin ex vivo. A scoping review catalogs iatrogenic botulism after botulinum toxin injections, highlighting risks with unlicensed products and underreported skin f
Summary
Today's top cosmetic-related studies span safety, mechanistic cosmeceuticals, and complication surveillance. A 90-day rat study delineates dose-dependent neurotoxicity of silver nanoparticles used in cosmetics, while hydroxyproline-containing cyclic dipeptides from collagen suppress UVB-induced inflammatory pathways and penetrate human skin ex vivo. A scoping review catalogs iatrogenic botulism after botulinum toxin injections, highlighting risks with unlicensed products and underreported skin findings.
Research Themes
- Cosmetic ingredient safety and toxicology
- Anti-photoaging cosmeceutical mechanisms
- Adverse event surveillance in aesthetic procedures
Selected Articles
1. Collagen-derived hydroxyproline-containing cyclic dipeptides prevent photoaging-related inflammatory response in UVB-irradiated epidermal keratinocytes.
Hydroxyproline-containing cyclic dipeptides, particularly cyclo(X-Hyp), attenuated UVB-induced ROS in human keratinocytes, dampened NF-κB/MAPK signaling, reduced MMP-2/9, and preserved type IV collagen. A cyclo(X-Hyp)-rich collagen hydrolysate (H-GDCH) recapitulated these effects, and cyclo(X-Hyp) achieved ~10% penetration into human dermatomed skin after 24 hours.
Impact: Identifies a potent, skin-penetrant cyclic dipeptide class with superior antioxidant and anti-inflammatory activity relevant to photoaging, offering a mechanistically supported cosmeceutical candidate.
Clinical Implications: Supports development of topical formulations leveraging cyclo(X-Hyp) or H-GDCH to mitigate photoaging by targeting ROS/NF-κB/MAPK and MMPs, guiding ingredient selection and dosing for cosmeceuticals.
Key Findings
- Cyclo(X-Hyp) reduced UVB-induced intracellular ROS more effectively than linear X-Hyp and cyclo(X-Pro).
- Downregulated NF-κB and MAPK activation with consequent suppression of MMP-2/MMP-9 and preservation of type IV collagen.
- Cyclo(X-Hyp) penetrated human dermatomed skin to ~10% within 24 hours; H-GDCH mirrored cellular protective effects.
Methodological Strengths
- Direct mechanistic assays in primary human epidermal keratinocytes with pathway readouts (NF-κB, MAPK, MMPs).
- Comparative evaluation versus linear and alternative cyclic dipeptides; ex vivo human skin penetration assay.
Limitations
- Preclinical in vitro and ex vivo data without in vivo human efficacy or safety trials.
- Long-term stability, formulation compatibility, and clinical dosing remain untested.
Future Directions: Conduct in vivo photoprotection studies, dermal PK/PD, irritation/sensitization assessments, and randomized clinical trials to validate anti-photoaging efficacy.
Reactive oxygen species (ROS) are major contributors to skin photoaging, which is cumulatively caused by sunlight exposure. We previously developed a unique collagen hydrolysate, named H-GDCH, enriched with hydroxyproline (Hyp)-containing cyclic dipeptides, cyclo(X-Hyp), using ginger protease and subsequent heat treatment. Here, we demonstrated the inhibitory effects of cyclo(X-Hyp) and H-GDCH on ultraviolet B (UVB)-induced photoaging-related inflammatory response in normal human epidermal keratinocytes (NHEK). Cyclo(X-Hyp) significantly decreased intracellular ROS generated by UVB irradiation. The ROS scavenging ability of cyclo(X-Hyp) was superior to that of the corresponding linear dipeptides (X-Hyp) and Pro-containing cyclic dipeptides [cyclo(X-Pro)], respectively. Cyclo(X-Hyp) suppressed ROS-induced activation of inflammatory pathways, including nuclear factor-κB and mitogen-activated protein kinases, and the subsequent increase in matrix metalloproteinase (MMP)-2/MMP-9; moreover, it inhibited the reduction of type IV collagen. ROS production and the downstream events simulated by UVB were also prevented by culturing with H-GDCH. Cyclo(X-Hyp) penetrated human dermatomed skin with high efficiency, reaching 10% after a 24-h incubation. These results indicate that cyclo(X-Hyp) and the cyclo(X-Hyp)-rich collagen hydrolysate, H-GDCH, have the potential as anti-photoaging agents in skin health applications, including cosmetics and functional foods.
2. Iatrogenic botulism following botulinum toxin injection: a scoping review of clinical characteristics, risk factors, and dermal considerations.
Across 113 cases of iatrogenic botulism, nearly half involved unlicensed BoNT products, with systemic symptoms usually within 4 days and prominent dysphagia, ptosis, and generalized weakness; respiratory failure occurred in 12.4%. Most patients recovered, often with antitoxin therapy, but skin reactions were inconsistently reported, indicating safety-reporting gaps.
Impact: Provides the most comprehensive synthesis to date of systemic risks and risk factors for BoNT-related botulism, directly informing aesthetic practice safety and regulatory oversight.
Clinical Implications: Use licensed BoNT products, adhere to dosing and technique, and establish protocols for early recognition and antitoxin access. Improve adverse event documentation, especially cutaneous signs, to refine risk mitigation.
Key Findings
- 46% of cases involved unlicensed BoNT products; females comprised 78.8% of cases.
- Symptom onset typically within 4 days: dysphagia 82.3%, ptosis 78.8%, generalized weakness 65.5%; respiratory failure in 12.4%.
- Treatments included antitoxin (59.3%) and pyridostigmine (24.8%); 86.7% fully recovered, though some had prolonged symptoms (>6 months).
Methodological Strengths
- PRISMA-ScR-guided multi-database search with explicit inclusion criteria.
- Aggregates quantitative details on products, dosing, routes, and outcomes across 113 cases.
Limitations
- Evidence base limited to case reports with heterogeneity and publication/reporting bias.
- Lack of denominator data precludes incidence estimation and risk stratification.
Future Directions: Establish standardized adverse event reporting for aesthetic BoNT, prospective registries, and pharmacovigilance linking product provenance with outcomes.
STUDY PURPOSE: Botulinum toxin (BoNT) is commonly used for both cosmetic and medical purposes. However, improper use can lead to iatrogenic botulism. This scoping review aimed to evaluate the systemic and skin-related effects, identify risk factors, and highlight safety gaps in BoNT-related botulism. METHODS: We followed PRISMA-ScR guidelines to search for literature from 1997 to 2024 across PubMed, Scopus, EMBASE, and Google Scholar. Ten case reports (113 patient cases) met the inclusion criteria. RESULTS: Females accounted for 78.8% of cases. Systemic symptoms typically developed within four days after the injection. Notably, 46% of cases involved unlicensed BoNT products, raising safety concerns. Among the licensed formulations, Abobotulinum toxin A accounted for 33.6% of cases, Onabotulinum toxin A for 10.6%, and other or unspecified products for 9.7%. Doses ranged from 100 to 2000 units (average of 487±312 units). Intramuscular injection was the most common method at 60.2%. Common symptoms included dysphagia in 82.3% of cases, ptosis in 78.8%, and generalized weakness in 65.5%. Respiratory failure occurred in 12.4% of severe cases. Interestingly, there were no consistent reports of skin or injection-site reactions, suggesting potential underreporting of skin-related effects. Treatments included antitoxin in 59.3% of cases and pyridostigmine in 24.8%. The majority of patients, 86.7%, fully recovered, though six experienced symptoms lasting over six months. CONCLUSION: Both licensed and unlicensed BoNT products can lead to iatrogenic botulism. Inconsistent reporting of skin complications highlights a gap in safety data. Adhering to proper injection protocols and thoroughly documenting adverse events is crucial for enhancing patient safety.
3. Dose-dependent neurotoxicity of starch-adorned silver nanoparticles: A chronic in vivo study.
In a 90-day oral exposure study in rats, starch-coated silver nanoparticles produced dose-dependent neurobehavioral deficits, neurotransmitter alterations, oxidative stress, DNA damage, and histopathologic changes, with dopaminergic pathways affected at very low doses. The NOAEL for brain effects was 10 μg/kg/day, underscoring potential CNS risks from chronic low-dose AgNP exposure.
Impact: Provides quantitative dose-response and NOAEL for AgNP neurotoxicity relevant to cosmetic and consumer exposure risk assessment, with multimodal mechanistic corroboration.
Clinical Implications: Supports stricter exposure limits and labeling for AgNP-containing cosmetic products; informs NGRA and regulatory safety margins by integrating dose thresholds and neurotoxicity endpoints.
Key Findings
- Dose-dependent impairments in spatial learning, memory, and locomotion at ≥500 μg/kg/day over 90 days.
- Neurotransmitter dysregulation: serotonin and acetylcholinesterase decreased at ≥100 μg/kg/day; dopamine decreased between 10–100 μg/kg/day.
- Oxidative stress, reduced antioxidant capacity, DNA damage (8-OHdG), apoptosis, and brain inflammation/degeneration; brain NOAEL determined as 10 μg/kg/day.
Methodological Strengths
- Chronic 90-day exposure with wide dose range and comprehensive neurobehavioral, biochemical, and histopathology endpoints.
- Evidence of brain deposition and pathway-level markers (oxidative stress, apoptosis) supporting mechanistic plausibility.
Limitations
- Rodent model without human exposure kinetics; generalizability to topical cosmetic exposure requires translation.
- Potential contribution of dissolved Ag+ versus particles not fully disentangled; coating-specific effects may vary.
Future Directions: Human-relevant exposure models (dermal, inhalational), TK/TD integration, and comparative studies across coatings to refine risk assessment for cosmetic applications.
Silver nanoparticles (AgNPs) are widely used in various fields, including medicine, food products, water filtration systems, cosmetics, textiles, and packaging, due to their powerful antimicrobial activity. However, chronic exposure to AgNPs was found to pose risks to human health owing to their highly reactive surface, large surface area, and the potential to penetrate the blood brain barrier (BBB). In this study, the effects of chronic oral administration of AgNPs on the cognitive and behavioral functions of rats were investigated, and the molecular mechanisms underlying AgNPs-induced neurotoxicity were reported. Male Wistar adult rats were orally administered doses ranging from 10 μg/kg body weight (BW) to 10 mg/kg BW/day for 90 days. Results revealed that the effects of chronic oral administration of AgNPs were dose dependent. Spatial learning, memory, and locomotor activity in rats were impaired at doses above 500 μg/kg BW/day. Significant decline in the levels of brain neurotransmitters, including serotonin and acetylcholinesterase, was observed at doses above 100 μg/kg BW/day. However, a significant reduction in dopamine levels was observed to be between 10 and 100 μg/kg BW/day, indicating that dopaminergic pathways are highly sensitive to AgNPs exposure, even at minimal concentrations. Interesentingly, increase in oxidative stress markers (ROS, protein carbonylation and MDA) at doses above 100 μg/Kg BW/day, decrease in antioxidant potential (GSH and TAC) at dose of 10 μg/Kg BW/day, induction of DNA damage (8-OHdG), and apoptosis in the brain at doses above 100 μg/Kg BW/day were observed. Furthermore, H&E staining and immunohistochemical analysis of brain tissue revealed inflammation, apoptosis and alterations in brain architecture, with signs of degeneration observed at doses starting from 10 μg/kg BW/day. The presence of AgNPs was also detected in the cerebral cortex of animals receiving 2 and 5 mg/kg BW/day. The no-observed-adverse-effect level (NOAEL) for chronic administration of starch-coated AgNPs on brain health was determined to be 10 μg/kg BW/day, demonstrating that even low-dose, long-term exposure to AgNPs poses significant risks to the central nervous system.